|Publication status||Published - 28 Dec 2015|
- myelodysplastic syndromes (MDS)
- acute myeloid leukemia (AML)
Liberante, F. G., Pouryahya, T., McMullin, M-F., Zhang*, S-D., & Mills*, K. I. (2015). Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget, 7(6).